十二氢咔唑 | 6326-88-1

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 十二氢咔唑
• 英文名称: dodecahydro-1H-carbazole
• 英文别名: N-ethyl-dodecahydrocarbazole；dodecahydrocarbazole；perhydrocarbazole；dodecahydro-carbazole；Dodecahydro-carbazol；Dodecahydrocarbazol；2,3,4,4a,4b,5,6,7,8,8a,9,9a-dodecahydro-1H-carbazole
• CAS: 6326-88-1
• 化学式: C₁₂H₂₁N
• mdl: MFCD00022214
• 分子量: 179.305
• InChiKey: SBVSDAFTZIVQEI-UHFFFAOYSA-N

物化性质

• 熔点：
  65 °C
• 沸点：
  124-125 °C(Press: 10 Torr)
• 密度：
  0.950±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

上下游信息

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	9-methyldodecahydrocarbazole	107663-60-5	C13H23N	193.332
  ——	dodecahydro-N-ethylcarbazole	146900-30-3	C14H25N	207.359

反应信息

• 作为反应物：
  描述：

  十二氢咔唑 在 chlorohydrido(2,6-bis(di-tert-butylphosphinito)phen-1-yl)iridium(III) 、 sodium t-butanolate 作用下， 反应 72.0h， 以92%的产率得到2,3,4,5,6,7,8,9-octahydro-1H-carbazole
  参考文献：
  名称：

  用铱钳催化剂对吲哚和咔唑分子进行无溶剂选择性脱氢。

  摘要：

  发现一种先前已知的铱POCOP夹钳催化剂选择性地使几个吲哚和咔唑分子的杂环部分脱氢。发现这些分子具有“活性窗口”（172-178℃），在该窗口上仅杂环经历了脱氢。所有反应均在无溶剂条件下进行，所选底物的收率非常好，并且通过蒸馏或氧化铝栓塞过滤分离了产物。

  DOI：

  10.1039/c4cc02073a
• 作为产物：
  描述：

  dicyclohexylidenehydrazine 在 盐酸 、 1,2,3,4-四氢萘 、 溶剂黄146 、 铂 作用下， 生成 十二氢咔唑
  参考文献：
  名称：

  The piloty cyclization of biscyclohexanone azine and the methylation of 1,2,3,4,5,6,7,8,-octahydrocarbazole

  摘要：

  DOI：

  10.1016/s0040-4020(01)98613-2

文献信息

• TROPAN COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1785421A1

  公开（公告）日：2007-05-16

  The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse ractions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R1, R2, R3 and R1 each a hydrogen atom or a substituent; R5 is a substituent; X- is an anion;the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.

  传统的抗胆碱药物通过吸入给药被认为可能加重与前列腺增生相关的排尿困难，并要求传统的抗胆碱药物通过吸入给药必须显示减少副作用或不良反应。 本发明涉及一种由通式（I）表示的化合物： （其中A代表; 和R1、R2、R3和R1分别是氢原子或取代基; R5是取代基; X-是阴离子;符号: 表示外向型或内向型，或它们的混合物），其盐或溶剂化产物。它们可用作通过胆碱受体介导的疾病的预防和/或治疗剂，具有减少副作用或不良反应。
• Use of Rylene Derivatives as Photosensitizers in Solar Cells
  申请人：Pschirer Neil Gregory

  公开号：US20080269482A1

  公开（公告）日：2008-10-30

  Use of rylene derivatives I with the following definition of the variables: X together both —COOM; Y a radical -L-NR 1 R 2 (y1) -L-Z-R 3 (y2) the other radical hydrogen; together both hydrogen; R is optionally substituted (het)aryloxy, (het)arylthio; P is —NR 1 R 2 ; B is alkylene; optionally substituted phenylene; combinations thereof; A is —COOM; —SO 3 M; —PO 3 M 2 ; D is optionally substituted phenylene, naphthylene, pyridylene; M is hydrogen; alkali metal cation; [NR 5 ] 4 + ; L is a chemical bond; optionally indirectly bonded, optionally substituted (het)arylene radical; R 1 , R 2 are optionally substituted (cyclo)alkyl, (het)aryl; together optionally substituted ring comprising the nitrogen atom; Z is —O—; —S—; R 3 is optionally substituted alkyl, (het)aryl; R′ is hydrogen; optionally substituted (cyclo)alkyl, (het)aryl; R 5 is hydrogen; optionally substituted alkyl (het)aryl; m is 0, 1, 2; n, p m=0: 0, 2, 4 where: n+p=2, 4, if appropriate 0; m=1: 0, 2, 4 where: n+p=0, 2, 4; m=2: 0, 4, 6 where: n+p=0, 4, 6, or of mixtures thereof as photosensitizers in solar cells.

  使用以下变量定义的莱伦衍生物I的用途： X一起 两者都是-COOM; Y是一个基团 -L-NR 1 R 2 (y1) -L-Z-R 3 (y2) 另一个基团是氢; 一起 两者都是氢; R可选择地被取代为(het)芳氧基，(het)芳基硫基; P是-NR 1 R 2 ; B是烷基; 可选择地被取代的苯基; 它们的组合; A是-COOM; -SO 3 M; -PO 3 M 2 ; D可选择地被取代为苯基，萘基，吡啶基; M是氢; 碱金属阳离子; [NR 5 ] 4 + ; L是化学键; 可选择地间接键合，可选择地被取代的(het)芳基基团; R 1 ，R 2 可选择地被取代的(环)烷基，(het)芳基; 一起可选择地被取代的环，其中包括氮原子; Z是-O-; -S-; R 3 可选择地被取代的烷基，(het)芳基; R′是氢; 可选择地被取代的(环)烷基，(het)芳基; R 5 是氢; 可选择地被取代的烷基(het)芳基; m为0, 1, 2; n, p, m=0: 0, 2, 4其中：n+p=2, 4，如果适用为0; m=1: 0, 2, 4其中：n+p=0, 2, 4; m=2: 0, 4, 6其中：n+p=0, 4, 6， 或者作为太阳能电池中的光敏剂的混合物。
• HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME
  申请人：EA PHARMA CO., LTD.

  公开号：US20160332999A1

  公开（公告）日：2016-11-17

  The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

  本发明提供了一种由公式(I)表示的化合物： 其中，每个符号如说明书中所定义，或者其药用可接受的盐。该化合物具有优越的TRPA1拮抗剂活性，并且可以提供一种用于预防或治疗涉及TRPA1拮抗剂和TRPA1的疾病的药物。
• Hydrogenation of arenes and N-heteroaromatic compounds over ruthenium nanoparticles on poly(4-vinylpyridine): a versatile catalyst operating by a substrate-dependent dual site mechanism
  作者：Minfeng Fang、Nataliya Machalaba、Roberto A. Sánchez-Delgado

  DOI：10.1039/c1dt10801h

  日期：——

  A nanostructured catalyst composed of Ru nanoparticles immobilized on poly(4-vinylpyridine) (PVPy) has been synthesized by NaBH4 reduction of RuCl3·3H2O in the presence of the polymer in methanol at room temperature. TEM measurements show well-dispersed Ru nanoparticles with an average diameter of 3.1 nm. Both powder XRD patterns and XPS data indicate that the Ru particles are predominantly in the zerovalent state. The new catalyst is efficient for the hydrogenation of a wide variety of aromatic hydrocarbons and N-heteroaromatic compounds representative of components of petroleum-derived fuels. The experimental data indicate the existence of two distinct active sites in the nanostructure that lead to two parallel hydrogenation pathways, one for simple aromatics involving conventional homolytic hydrogen splitting on Ru and a second one for N-heteroaromatics taking place via a novel heterolytic hydrogen activation on the catalyst surface, assisted by the basic pyridine groups of the support.

  通过在室温下将RuCl3·3H2O在聚(4-乙烯基吡啶)(PVPy)存在下用NaBH4还原于甲醇中，合成了一种由Ru纳米颗粒固定在PVPy上的纳米结构催化剂。TEM测量显示，平均直径为3.1 nm的良好分散Ru纳米颗粒。粉末XRD图谱和XPS数据显示，Ru颗粒主要处于零价态。这种新型催化剂对广泛芳香烃和代表石油衍生燃料成分的N-杂芳香化合物的氢化反应效率高。实验数据表明，纳米结构中存在两种不同的活性位点，导致两种平行的氢化途径，一种是对简单芳香烃，涉及Ru上的传统均裂氢裂解，另一种是对N-杂芳香化合物，通过催化剂表面上的新型异裂氢活化进行，得到了载体中碱性吡啶基团的辅助。
• CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME
  申请人：EA PHARMA CO., LTD.

  公开号：EP3330266A1

  公开（公告）日：2018-06-06

  A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof has superior TRPA1 antagonist activity, and the compound or a pharmaceutically acceptable salt thereof is useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

  化合物的化学式为(I)： 其中每个符号的定义如描述中所定义， 或其药学上可接受的盐具有优越的TRPA1拮抗活性，该化合物或其药学上可接受的盐对涉及TRPA1拮抗剂和TRPA1的疾病的预防或治疗是有用的。

表征谱图